Treprostinil Data Presented at American Thoracic Society Conference Demonstrates Significant Clinical Progress in All Four Routes of Admi...( First Presentation of Full Data Set...),Health

First Presentation of Full Data Set from the TRIUMPH-1 Trial of Inhaled

Treprostinil

SILVER SPRING, Md., May 21 /PRNewswire-FirstCall/ -- United Therapeutics Corporation (Nasdaq: UTHR) and its wholly-owned subsidiary Lung Rx, Inc. today announced that data from seven presentations concerning the treatment of pulmonary arterial hypertension (PAH) with treprostinil were reported at the American Thoracic Society (ATS) meeting in Toronto, Ontario. The ATS presentations involved treprostinil delivered by inhaled, oral, intravenous and subcutaneous routes of administration.

"It has always been our goal to build a portfolio of products from the remarkable treprostinil molecule that will create viable treatment options for patients along the full continuum of this life-threatening disease," said Martine Rothblatt, Ph.D., United Therapeutics' Chairman and Chief Executive Officer. "The results of these diverse studies covering all four routes of delivery are bringing us just that much closer to realizing our goal."

Inhaled Treprostinil

In TRIUMPH-1: Discussion of Inhaled Treprostinil Sodium in Patients with PAH, Dr. Vallerie McLaughlin, Director of the Pulmonary Hypertension Program at the University of Michigan, presented the full data set from the TRIUMPH-1 study of investigational inhaled treprostinil. Dr. McLaughlin's presentation confirmed that six-minute walk (6MW) distance increased by approximately 20 meters in patients receiving inhaled treprostinil as compared to patients receiving placebo, with a durable and significant effect on 6MW distance observed at trough exposure.

Dr. McLaughlin also presented data showing that inhaled treprostinil improved both quality of life and
'/>"/>